Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 FDA Affirms GRAS Status for Ahiflower Oil - Nutraceuticals World

What are you searching for?

Sign in
Regulations

FDA Affirms GRAS Status for Ahiflower Oil

By: Lisa Olivo

, Rodman Media

Technology Crops International (TCI), Winston-Salem, NC, was issued a letter of no objection from the U.S. Food and Drug Administration for TCI’s self-affirmed GRAS filing of Buglossoides arvensis oil (trade name: Ahiflower oil). This proprietary omega-rich dietary oil contains the highest levels of non-GM omega-3 essential fatty acids among commercially available dietary plant oils, combining ALA (alpha linolenic acid) and a uniquely high level of SDA (stearidonic acid). Ahiflower also contains significant levels of GLA (gamma linolenic acid), an omega-6 essential fatty acid, and oleic acid, an omega-9 fatty acid.
 
Ahiflower is a more efficient omega-3 alternative to flax, chia, and other ALA-rich dietary oils because the SDA content of Ahiflower oil metabolizes to EPA (eicosapentaenoic acid) as much as 3 times more effectively than equivalent amounts of ALA. EPA is commonly sourced from fish oils. Results from a recently-concluded double-blind placebo-controlled human clinical trial, which compares Ahiflower oil utilization to that of flax, will be published early in 2015.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters

Topics